InMed 10-K: Going Concern, $2.2M Cash, Merger with Mentari Pending
INM has more than doubled off its 52-week low of $0.575 on light trading volume (0.1× avg).
Summary
InMed's FY2026 10-K shows a going concern qualification, $2.2M cash runway into September 2026, and a $12.6M net loss. The pending Mentari reverse merger is the primary path forward; failure could lead to liquidation.
Key Events · Earnings and Guidance · INM
-
Going Concern Qualification
Auditor CBIZ CPAs P.C. included an explanatory paragraph stating substantial doubt about InMed's ability to continue as a going concern. Cash of $2.2M as of June 30, 2026 funds operations only into the end of Q3 calendar 2026.
-
FY2026 Net Loss Widens to $12.6M
Net loss increased 54% from $8.2M in FY2025 to $12.6M in FY2026. Accumulated deficit reached $130.2M. Operating expenses rose 37% to $11.6M, driven by $1.46M intangible asset impairment and higher G&A.
-
BayMedica Wind-Down Completed
The only revenue-generating segment was wound down by June 30, 2026. InMed incurred $555K in severance costs and expects ~$120K more. Discontinued operations swung from $528K income in FY2025 to a $1.19M loss in FY2026.
-
Patent License Arbitration Narrowed
Arbitrator struck most claims on June 1, 2026, leaving only the claim for ~$3.4M annual minimum payments (2022-2024) plus ~$2.3M ongoing. An unfavorable outcome would be material against $1.1M shareholders' equity.
Analysis · INM · Life Sciences
InMed's FY2026 annual report confirms the company is running on fumes. The auditor issued a going concern qualification, cash of $2.2M funds operations only into September 2026, and the company has wound down its only revenue-generating segment. The pending reverse merger with Mentari Therapeutics is the lifeline — if it fails, the board may pursue dissolution and liquidation. The arbitration claim against BayMedica has narrowed but still seeks ~$5.7M in minimum payments, which would be material against InMed's $1.1M shareholders' equity. This filing establishes the financial baseline that makes the merger outcome binary for existing shareholders.
How filings like this one have moved
In the 30 days to Sep 9, 2026, 44.3% of the 601 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INM was trading at $1.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.58 to $2.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.